Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

February 15, 2005 (Vol. 25, No. 4)

Personalized Arthritis Therapy

With Blockbuster Drugs in Jeopardy Firms Look to Pharmacogenetics

  • Recent reports of an increased risk of heart attack with the Cox-2 inhibiting drugs Vioxx and Celebrex have resulted in a huge setback for arthritis therapeutics. These drugs had become staples for the treatment of osteoarthritis (OA) and rheumatoid arthritis, both debilitating inflammatory diseases. It seems that the ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.